COVID-19疫情期间黑人与白人前列腺癌治疗差异评估
这项多中心回顾性队列研究比较了COVID-19疫情第一波期间(2020年3月16日至5月15日,269例)与疫情前(2019年3月11日至5月10日,378例)未治疗非转移性前列腺癌黑人与白人患者的前列腺切除术率。结果显示,疫情期间黑人患者接受前列腺切除术的几率显著低于白人患者(1.3% vs 25.9%,P < .001),而疫情前两组无差异;调整年份交互项后,黑人患者疫情期手术几率OR为0.06(95%CI 0.01-0.35;P = .002),白人患者为1.41(95%CI 0.81-2.44;P = .23)。
要点
- 疫情期间黑人非转移性前列腺癌患者前列腺切除术率仅1.3%,远低于白人患者的25.9%。
- 疫情前黑人与白人前列腺切除术率无显著差异(17.7% vs 19.1%,P = .75)。
- 手术量减少幅度越大的中心,其服务的黑人患者比例越高。
核心结论
- 在COVID-19疫情第一波期间,黑人非转移性前列腺癌患者接受前列腺切除术的几率显著低于白人患者。
研究设计与样本
- 多中心、区域协作的回顾性队列研究,比较疫情期(2020年3月16日至5月15日,269例)与疫情前(2019年3月11日至5月10日,378例)未治疗非转移性前列腺癌患者的前列腺切除术率。
主要发现
- 疫情期间黑人患者前列腺切除术率为1.3%(1/76),白人患者为25.9%(50/193),P < .001。
- 疫情前黑人患者前列腺切除术率为17.7%(17/96),白人患者为19.1%(54/282),P = .75。
- 黑人患者活检前中位PSA水平为8.8 ng/mL(IQR 5.3-15.2),白人患者为7.2 ng/mL(IQR 5.1-11.1),P = .04。
- 交互项分析显示,疫情期间黑人患者手术几率OR为0.06(95%CI 0.01-0.35;P = .002),白人患者为1.41(95%CI 0.81-2.44;P = .23)。
- 手术量变化因中心而异(从增加33%到完全暂停),手术量减少最大的中心服务的黑人患者比例更高。
临床怎么用
- 临床应关注疫情期间黑人前列腺癌患者手术机会的显著下降,警惕医疗资源重新分配加剧的种族差异。
- 在公共卫生危机中需制定平衡的缓解策略,确保癌症治疗资源的公平分配。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Early in the COVID-19 pandemic, racial/ethnic minority communities disproportionately experienced poor outcomes; however, the association of the pandemic with prostate cancer (PCa) care is unknown. OBJECTIVE: To assess the association between race and PCa care delivery for Black and White patients during the first wave of the COVID-19 pandemic. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, regional, collaborative, retrospective cohort study compared prostatectomy rates between Black and White patients with untreated nonmetastatic PCa during the COVID-19 pandemic (269 patients from March 16 to May 15, 2020) and prior (378 patients from March 11 to May 10, 2019). MAIN OUTCOMES AND MEASURES: Prostatectomy rates. RESULTS: Of the 647 men with nonmetastatic PCa, 172 (26.6%) were non-Hispanic Black men, and 475 (73.4%) were non-Hispanic White men. Black men were significantly less likely to undergo prostatectomy during the pandemic compared with White patients (1 of 76 [1.3%] vs 50 of 193 [25.9%]; P < .001), despite similar COVID-19 risk factors, biopsy Gleason grade groups, and comparable prostatectomy rates prior to the pandemic (17 of 96 [17.7%] vs 54 of 282 [19.1%]; P = .75). Black men had higher median prostate-specific antigen levels prior to biopsy (8.8 ng/mL [interquartile range, 5.3-15.2 ng/mL] vs 7.2 ng/mL [interquartile range, 5.1-11.1 ng/mL]; P = .04). A linear combination of regression coefficients with an interaction term for year demonstrated an odds ratio for likelihood of surgery of 0.06 (95% CI, 0.01-0.35; P = .002) for Black patients and 1.41 (95% CI, 0.81-2.44; P = .23) for White patients during the pandemic compared with prior to the pandemic. Changes in surgical volume varied by site (from a 33% increase to complete shutdown), with sites that experienced the largest reduction in cancer surgery caring for a greater proportion of Black patients. CONCLUSIONS AND RELEVANCE: In this large multi-institutional regional collaborative cohort study, the odds of PCa surgery were lower among Black patients compared with White patients during the initial wave of the COVID-19 pandemic. Although localized PCa does not require immediate treatment, the lessons from this study suggest systemic inequities within health care and are likely applicable across medical specialties. Public health efforts are needed to fully recognize the unintended consequence of diversion of cancer resources to the COVID-19 pandemic to develop balanced mitigation strategies as viral rates continue to fluctuate.
引用
- Bernstein AN, Talwar R, Handorf E, et al. Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic. JAMA Oncol. 2021. PMID: 34292311. doi:10.1001/jamaoncol.2021.2755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。